Abstract
Premature ovarian insufficiency (POI) represents a condition characterized by the absence of normal ovarian function due to an incipient (by 3–10 years) ovarian aging. In most of the women affected there are no signs or symptoms that precede the interruption of menstruation and the onset of POI and the majority of women have a normal history of menarche, regular menstrual cycles and normal fertility. The possible genetic role in the development of POI has been largely demonstrated and many genes have been involved; on the other hand, ovary is not protected immunologically and the detection of autoantibodies directed against various ovarian targets strongly support the hypothesis of an autoimmune etiology. In approximately 5–10 % of women with a diagnosis of POI with a normal karyotype, a spontaneous pregnancy could occur even if the recovery of ovarian function is temporary and poorly predictable. Embryo donation and adoption are other alternatives that should be considered. POI and subsequent loss of reproductive capacity is a devastating condition and a difficult diagnosis for women to accept so it requires an individualized and a multidisciplinary approach. Hormonal replacement therapy (HRT) should be commenced as soon as possible to prevent and to contrast the onset of the symptoms related to hypoestrogenism and to improve the quality of life for these women.
Similar content being viewed by others
References
Cox L, Liu JH (2014) Primary ovarian insufficiency: an update. Int J Womens Health 20(6):235–243
ESHRE Capri Workshop Group (2005) Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 11:513–525
Broekmans FJ, Soules MR, Fauser BC (2009) Ovarian aging: mechanisms and clinical consequences. Endocr Rev 30:465–493
Van Asselt KM, Kok HS, Pearson PL et al (2004) Heritability of menopausal age in mothers and daughters. Fertil Steril 82:1348–1351
Janse F, Knauff EA, Niermeijer MF et al (2010) Dutch Premature Ovarian Failure Consortium. Similar phenotype characteristics comparing familial and sporadic premature ovarian failure. Menopause 17:758–765
Cordts BC, Christofolini DM, Dos Santos AA, Bianco B, Barbosa CP (2011) Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet 283:635–643
Karnis MF (2012) Fertility, pregnancy, and medical management of Turner syndrome in the reproductive years. Fertil Steril 98:787–791
Bidet M (2011) Resumption of Ovarian Function and Pregnancies in 358 Patients with Premature Ovarian Failure. J Clin Endocrinol Metab 96:3864–3872
Sullivan AK, Marcus M, Epstein MP et al (2005) Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 20:402–412
Otsuka F, McTavish KJ, Shimasaki S (2011) Integral role of GDF-9 and BMP-15 in ovarian function. Mol Reprod Dev 78:9–21
Yoon SH, Choi YM, Hong MA et al (2010) Estrogen receptor alpha gene polymorphisms in patients with idiopathic premature ovarian failure. Hum Reprod 25:283–287
Rafique S, Sterling E, Lawrence N (2012) A new approach to primary ovarian insufficiency. Obstet Gynecol Clin N Am 39:567–586
Hoek A, Schoemaker J, Drexhage HA (1997) Premature ovarian failure and ovarian autoimmunity. Endocr Rev 18:107–134
La Marca A, Marzotti S, Brozzetti A et al (2009) Italian Addison Network. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J Clin Endocrinol Metab 94:3816–3823
Bedoschi G, Turan V, Oktay K (2013) Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: is it protective? Curr Breast Cancer Rep 5:302–308
Trikudanathan S, Pedley A, Massaro JM et al (2013) Association of female reproductive factors with body composition: the Framingham Heart Study. J Clin Endocrinol Metab 98:236–244
Kinney A, Kline J, Kelly A, Reuss ML, Levin B (2007) Smoking, alcohol and caffeine in relation to ovarian age during the reproductive years. Hum Reprod 22:1175–1185
Iorio R, Castellucci A, Ventriglia G et al (2014) Ovarian toxicity: from environmental exposure to chemotherapy. Curr Pharm Des 20:5388–5397
Knauff EAH, Eijkemans MJC, Lambalk CB et al (2009) Anti-Műllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 94:786–792
Van der Steeg JW, Steures P, Eijkemans MJ et al (2007) Predictive value and clinical impact of basal follicle-stimulating hormone in subfertile, ovulatory women. J Clin Endocrinol Metab 92:2163–2168
Van Disseldorp J, Lambalk CB, Kwee J et al (2010) Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 25:221–227
Luisi S, Ciani V, Podfigurna-Stopa A et al (2012) Serum anti-Müllerian hormone, inhibin B, and total inhibin levels in women with hypothalamic amenorrhea and anorexia nervosa. Gynecol Endocrinol 28:34–38
Andersen CY, Byskov AG (2006) Estradiol and regulation of anti-Müllerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles’ fluid. J Clin Endocrinol Metab 91:4064–4069
Silberstein T, MacLaughlin DT, Shai I et al (2006) Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod 21:159–163
Kalantaridou SN, Naka KK, Bechlioulis A, Makrigiannakis A, Michalis L, Chrousos GP (2006) Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol Metab 17:101–109
Rocca WA, Bower JH, Maraganore DM et al (2008) Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70:200–209
Primary ovarian insufficiency in adolescent and young women. Committee Opinion. No 605. ACOG. Obstet and Gynecol 2014, 123: 193-7
Rebar RW (2009) Premature ovarian failure. Obstet Gynecol 113:1355–1363
Parker WH, Broder MS, Chang E et al (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstet Gynecol 113:1027–1037
Nelson LM (2009) Clinical practice. Primary ovarian insufficiency. N Engl J Med 360:606–614
Scarabin PY, Oger E, Plu-Bureau G (2003) Estrogen and ThromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362:428–432
Bachmann G, Bancroft J, Braunstein G et al (2002) Princeton. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 77:660–665
Martyn-St James M, Carroll S (2008) Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone 43:521–531
De Caro JJ, Dominguez C, Sherman SL (2008) Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile x-associated primary ovarian insufficiency. Ann N Y Acad Sci. 1135:99–111
Lucas K, Hensel D (2014) Fertility preservation options for women treated for cancer. Nurs Womens Health 18:138–147
Krieg SA, Henne MB, Westphal LM (2008) Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in vitro fertilization pregnancies. Fertil Steril 90:65–70
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Luisi, S., Orlandini, C., Regini, C. et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J Endocrinol Invest 38, 597–603 (2015). https://doi.org/10.1007/s40618-014-0231-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-014-0231-1